Synaffix Entered into a License Agreement with Chong Kun Dang Pharm for ADC Technology
Shots:
- Synaffix received up front and is eligible to receive milestones representing a total deal value of $132M along with royalties on commercial sales. The agreement combines CKD Pharm’s existing oncology expertise and related technologies with the ADC platform of Synaffix to develop a novel ADC candidate for CKD's pipeline
- CKD will get the global right to use Synaffix's ADC technologies, comprising GlycoConnect, HydraSpace, and an undisclosed linker payload from the toxSYN platform
- CKD will be responsible for the research, development, manufacturing, and commercialization of the ADCs while Synaffix will lead the manufacturing of components related to its proprietary technologies
Ref: PRNewswire | Image: Synaffix
Related News:- Synaffix Entered into a License Agreement with Amgen to Develop Antibody-Drug Conjugates to Treat Cancer
Click here to read the full press release
Neha is a Senior Editor at PharmaShots. She is passionate and very enthusiastic about recent updates and developments in the life sciences and pharma industry. She covers Biopharma, MedTech, and Digital health segments along with different reports at PharmaShots. She can be contacted at connect@pharmashots.com.
